1. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
- Author
-
Marco Rossi, Michele Cimminiello, Barbara Loteta, Giovanni Tripepi, Antonella Morabito, Vanessa Innao, Annalisa Pitino, Virginia Naso, Tiziana Moscato, Mercedes Gori, Giuseppe Alberto Gallo, Giuseppe Console, Anna Ferreri, Massimo Martino, Donato Mannina, Massimo Gentile, Iolanda Vincelli, Pasquale Fabio Provenzano, and Anna Grazia Recchia
- Subjects
Male ,Melphalan ,medicine.medical_specialty ,Filgrastim ,Urology ,Neutropenia ,Polyethylene Glycols ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Autologous stem-cell transplantation ,medicine ,Humans ,Prospective Studies ,Autografts ,Multiple myeloma ,Aged ,business.industry ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,030220 oncology & carcinogenesis ,Autologous stem cell transplant ,G-CSF ,High dose melphalan ,Lipegfilgrastim ,Female ,Multiple Myeloma ,Stem Cell Transplantation ,Absolute neutrophil count ,business ,Pegfilgrastim ,030215 immunology ,medicine.drug - Abstract
G-CSF administration after high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to expedite neutrophil recovery. Several studies comparing filgrastim and pegfilgrastim in the post-ASCT setting concluded that the two are at least equally effective. Lipegfilgrastim (LIP) is a new long-acting, once-per-cycle G-CSF. This multicentric, prospective study aimed to describe the use of LIP in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (ASCT) and compare LIP with historic controls of patients who received short-acting agent (filgrastim [FIL]). Overall, 125 patients with a median age of 60 years received G-CSF after ASCT (80 patients LIP on day 1 post-ASCT and 45 patients FIL on day 5 post-ASCT). The median duration of grade 4 neutropenia (absolute neutrophil count [ANC]
- Published
- 2019